Bloomberg News

Sequenom Accuses Aria, Natera of Patent Infringement

January 26, 2012

(Corrects to show that Isis Innovation Ltd. licensed patent to Sequenom in fourth paragraph.)

Jan. 25 (Bloomberg) –- Sequenom Inc., which uses genetic analysis to diagnose conditions such as Down Syndrome, sued Aria Diagnostics Inc. and Natera Inc., claiming they infringed a patent used for non-invasive prenatal testing.

Aria and Natera are accused of developing prenatal tests using methods covered by a patent exclusively licensed to Sequenom in the U.S., according to separate complaints filed yesterday in federal court in San Diego, where Sequenom is based.

Sequenom, which calls itself “a pioneer in bringing non- invasive prenatal testing to the market,” said its claims “relate to nuclecic acid analysis and prenatal diagnosis.

Earlier complaints filed by Aria and Natera seek a judge’s declaration that they haven’t infringed the patent at issue, No. 6,258,540, which Sequenom licensed from U.K.-based Isis Innovation Ltd. Natera said Sequenom’s claims of the 540 patent are invalid.

Representatives of Aria and Natera didn’t immediately respond to phone and e-mail messages seeking comment yesterday after regular business hours on Sequenom’s complaints.

The cases are Sequenom Inc. v. Natera Inc. 12-cv-0184, and Sequenom v. Aria Diagnostics Inc., 12-cv-0189, U.S. District Court, Southern District of California (San Diego).

--Editors: Peter Blumberg, Joe Schneider

To contact the reporter on this story: Peter Blumberg in San Francisco at pblumberg1@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus